The global apheresis market size reached US$ 2.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2028, exhibiting a growth rate (CAGR) of 7.55% during 2023-2028.
Apheresis is a procedure of separating donated blood components, such as red blood cells (RBCs), white blood cells (WBCs), platelets, and plasma, to treat various diseases. It assists in treating sickle cell disease wherein red blood cells (RBCs) are shaped abnormally and cannot carry oxygen through the body. It is also employed to remove abnormal white blood cells (WBCs) that thicken the blood and interfere with organ function. In addition, as it aids in treating blood cancers and blood disorders, such as myasthenia gravis and thrombotic thrombocytopenic purpura (TTP), apheresis is widely used in blood collection centers, hospitals, and ambulatory centers across the globe.
Apheresis Market Trends:
The growing demand for apheresis to treat various diseases, such as autoimmune hemolytic anemia, acute disseminated encephalomyelitis, and cardiac neonatal lupus, represents one of the key factors driving the market. Besides this, there is a rise in the utilization of apheresis to collect plasma for treating burnt and trauma patients across the globe. This, along with the burgeoning healthcare industry, is contributing to the growth of the market. Moreover, increasing investments by key market players in research and development (R&D) activities to introduce an enhanced blood purification device that treats severe forms of arteriosclerosis obliterans is positively influencing the market. In addition, the rising demand for source plasma to treat primary immunodeficiency and hemophilia is offering lucrative growth opportunities to industry investors. Apart from this, the growing employment of apheresis as a therapy for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure, is offering a positive market outlook. Additionally, the increasing awareness among the masses about the benefits of apheresis is bolstering the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global apheresismarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, product, technology, procedure, application and end user.
Breakup by Component:
Leukocytes (Leukapheresis or Leukopheresis)
Lymphocytes (Lymphopheresis or Lymphapheresis)
Breakup by Product:
Disposables and Reagents
Breakup by Technology:
Breakup by Procedure:
Breakup by Application:
Breakup by End User:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation).
Base Year of the Analysis
Component, Product, Technology, Procedure, Application, End User, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited) and Terumo Bct Inc. (Terumo Corporation)
10% Free Customization
Report Price and Purchase Option
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global apheresis market was valued at US$ 2.7 Billion in 2022.
We expect the global apheresis market to exhibit a CAGR of 7.55% during 2023-2028.
The growing utilization of apheresis in blood collection centers, hospitals, ambulatory centers, etc., as it assists in treating blood disorders, such as myasthenia gravis and Thrombotic Thrombocytopenic Purpura (TTP), is primarily driving the global apheresis market.
The sudden outbreak of the COVID-19 pandemic had led to postponement of elective surgeries for sickle cell disease, autoimmune hemolytic anemia, cardiac neonatal lupus, etc., to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals, thereby negatively impacting the global market for apheresis.
Based on the component, the global apheresis market has been bifurcated into plasma (plasmapheresis), platelets (plateletpheresis), leukocytes (leukapheresis or leukopheresis), lymphocytes (lymphopheresis or lymphapheresis), and RBC's (erythropheresis). Among these, plasma (plasmapheresis) currently accounts for the largest market share.
Based on the product, the global apheresis market can be segmented into devices, disposables and reagents, and software. Currently, disposables and reagents hold the majority of the total market share.
Based on the technology, the global apheresis market has been divided into centrifugation, membrane separation, and selective adsorption. Among these, centrifugation currently exhibits a clear dominance in the market.
Based on the procedure, the global apheresis market can be categorized into donor/automated apheresis and therapeutic apheresis. Currently, donor/automated apheresis accounts for the majority of the global market share.
Based on the application, the global apheresis market has been segregated into renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and others, where hematological disorders currently hold the largest market share.
Based on the end user, the global apheresis market can be bifurcated into blood centers, hospitals, and others. Currently, blood centers exhibit a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global apheresis market include Asahi Kasei Medical Co. Ltd. (Asahi Kasei Corporation), B. Braun SE, Charles River Laboratories International Inc., Fresenius Medical Care AG & Co. KGaA, Haemonetics Corporation, Haier Biomedical, Kaneka Corporation, Medica S.p.a., Miltenyi Biotec, Nikkiso Co. Ltd., Sb-Kawasumi Laboratories Inc. (Sumitomo Bakelite Company Limited), and Terumo Bct Inc. (Terumo Corporation).
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.